In focus · trending topic

Immuron

15 stories · following the connections

Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

By Nasdaq OMXMay 8, 2018, 1:43 AM UTC

UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow

By Nasdaq OMXMar 13, 2018, 6:15 AM UTC

Immuron Commences US Non-Deal Institutional Investor Roadshow

By Nasdaq OMXMar 12, 2018, 12:17 PM UTC

Immuron Limited Issues Correction to Misleading Halt Announcement Headline

By Nasdaq OMXMar 7, 2018, 10:06 PM UTC

Travelan® Revenue Grows Significantly in US and Australia

By Nasdaq OMXFeb 16, 2018, 2:30 PM UTC

Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)

By Nasdaq OMXJan 31, 2018, 2:30 PM UTC

US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella

By Nasdaq OMXJan 29, 2018, 2:20 PM UTC

CEO to Present on US Investor TV Show and at Biotech Conference

By Nasdaq OMXJan 10, 2018, 2:04 PM UTC